Successful use of Rituximab in Evans syndrome and refractory immune thrombocytopenic purpura

Muhammad Kashif, Adnan Qureshi, Salman Naseem Adil, Mohammad Khurshid

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Immune cytopenias are mediated by auto-antibodies produced by B-lymphocytes. Conventional treatment of immune-mediated haematological disorders includes immunosuppression with steroids and other immune modulating therapies and in some refractory cases, splenectomy. Response rates to conventional and second-line agents are variable and a proportion of patients require lifelong immunosuppression to maintain the disease in remission. Rituximab, an anti- CD 20 monoclonal antibody has gained widespread acceptance in the management of Bcell malignancies. Additionally, it has been used to treat the disorders associated with autoantibody production. We report herein the successful use of Rituximab in the treatment of two patients with autoimmune cytopenias one had Evan's syndrome and other had refractory immune thrombocytopenic purpura. Both of these patients are still in remission at 16 and 25 months following treatment.

Original languageEnglish
Pages (from-to)64-65
Number of pages2
JournalJournal of the Pakistan Medical Association
Issue number1
Publication statusPublished - Jan 2010


Dive into the research topics of 'Successful use of Rituximab in Evans syndrome and refractory immune thrombocytopenic purpura'. Together they form a unique fingerprint.

Cite this